Navigation Links
IU, Regenstrief study: New noninvasive colorectal cancer screening tool highly accurate
Date:3/19/2014

INDIANAPOLIS -- An Indiana University and Regenstrief Institute study of nearly 10,000 average-risk, asymptomatic men and women from 90 sites across the United States reports that a multi-target stool DNA test -- a new noninvasive colorectal cancer screening tool that has not yet been approved for sale by the Food and Drug Administration -- detects 92.3 percent of colon cancers, compared to only 73.8 percent of cancers detected by a fecal immunochemical test, the most commonly used noninvasive test today.

Study results were published online March 19 and in the April 3 print issue of the New England Journal of Medicine.

Approximately nine out of 10 Americans older than 50 are thought to be at average risk for colon cancer. Sensitivity -- the ability of a test to detect disease -- is the most important characteristic for cancer screening tests because their primary role is to "rule out" disease.

The multi-target stool DNA analysis is conducted on a single stool sample expelled from the body directly into a container and mailed to a laboratory. The new test, which looks for human DNA mutations present in the stool as well as fecal blood, identified a significantly higher number of colorectal cancers compared to the current standard noninvasive method: fecal immunochemical test, or FIT. The study found that FIT identified 73.8 percent of colon cancers, about 20 percent fewer than the new multi-target stool DNA test. Colonoscopy, which is presumed to find all colon cancers, was the "gold standard" used as the reference method in the study.

The multi-target stool DNA test's ability to identify cancer did not vary in a statistically significant way by either cancer stage or location within the colon.

"While screening has been shown to reduce both the occurrence of and death rates from colorectal cancer, not enough people get screened," said lead author Thomas F. Imperiale, M.D., of the Indiana University Scho
'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-843-2276
Indiana University
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. IU, Regenstrief automated system aims to improve child health
2. Regenstrief and IHTSDO start collaborative efforts
3. Merck and Regenstrief Institute establish evidence-based care collaboration
4. Regenstrief study finds that generic drugs often have incorrect safety labeling
5. Regenstrief investigator inducted into medical informatics honor society
6. Regenstrief study: Informatics tools underutilized in prevention of hospital-acquired infection
7. Regenstrief and IU study investigates older adults views on cancer screening
8. IU, Regenstrief initiative aims to decrease hospitalization of nursing home residents
9. Regenstrief and IU study: Older adults with severe mental illness challenge healthcare system
10. CHICA, automated system developed by Regenstrief and IU, improves autism screening rate
11. RSNA and Regenstrief Institute launch effort to unify radiology procedure naming
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
IU, Regenstrief study: New noninvasive colorectal cancer screening tool highly accurate
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... Tbdress.com has recently announced that its Special ... 2014. The special offer will provide ladies many gorgeous shoes ... the world’s largest women’s dresses retailers, and its shoes include ... great discounts on that day: Everything at Tbdress.com is up ... above $89). , People can use the following coupon codes ...
(Date:11/23/2014)... SUNDAY, Nov. 23, 2014 (HealthDay News) -- The holidays ... autism because sensory overload can trigger major meltdowns, an ... under the best of circumstances, but when you have ... Varleisha Gibbs, an occupational therapy professor at University of ... release. "It,s best to let your hosts or ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 “BlackVue” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... unique and powerful options in the car camera industry. ... and it can be hard to find the one ...
Breaking Medicine News(10 mins):Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... ... ... ... ...
... ... ... ... ...
... ... ... , ... TULSA, Okla. , Feb. 19 U.S. ...
... more fumes that are likely carcinogenic than with electric ranges ... hot stove -- make that a hot gas ... cancer. , Researchers in Norway have found that cooking with ... , But, in a report published online Feb. 17 in ...
... (P4P) programs are payment models that reward workers for ... the healthcare setting, P4P programs use a variety of ... fee differentials and bonuses. A new study ... that P4P programs appear to be effective in incentivizing ...
... ... momentum created by local communities and the NGO Tostan to end the practice by 2015 ... Dakar, Senegal (PRWEB) February ... cutting (FGC) which has seen thousands of communities in Senegal join its ranks in recent ...
Cached Medicine News:Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 2Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 3Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 4Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 2Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 3Health News:Gas Cooking Might Up Your Cancer Risk 2Health News:Gas Cooking Might Up Your Cancer Risk 3Health News:Senegal: Total End of Female Genital Cutting Now in Sight 2
(Date:11/24/2014)... , Nov. 24, 2014 The Female Health ... an investor conference call to discuss its operating results ... 30, 2014 on Tuesday, December 2, 2014 at 11:00 ... report its operating results earlier the same day. ... the conference call by dialing 1-877-374-8416 (international participants dial ...
(Date:11/24/2014)... Nov. 24, 2014  GlySens Incorporated announced today that ... grant from the National Institute of Diabetes and Digestive ... Institutes of Health (NIH).  The grant is intended to ... ICGM™ long term implantable glucose monitoring system.  Final preparations ... is expected to begin before the end of 2014. ...
(Date:11/24/2014)... DEVON, England , Nov. 24, 2014 /PRNewswire/ ... https://www.facebook.com/PifflersUnited announced the release of results ... pain therapy device, in the self-management of fibromyalgia ... the area of worst pain, very significant clinically ... The 140 group members with fibromyalgia used ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... today that eleven presentations or publications on pre-clinical and ... several major tumor types will be made during the ... May 29-June 2, in Orlando, Florida. Abstracts are ... http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate Cancer ...
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the ... X 2), did not alter the median time it took ... reached in the subjects evaluated. In the same study, ...
Cached Medicine Technology:Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Medicine Products: